Hims & Hers Health (NYSE:HIMS) Hits New 12-Month Low – What’s Next?

Hims & Hers Health, Inc. (NYSE:HIMS) hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $15.46 and last traded at $16.4940, with a volume of 4912810 shares trading hands. The stock had previously closed at $15.84.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers agreed to buy Australian digital-telehealth leader Eucalyptus in a transaction valued at about $1.15 billion, giving HIMS immediate international scale and a foothold in Australia — a clear growth signal that likely underpins the stock’s uptick. Hims & Hers Stock Jumps on $1.15 Billion Deal to Acquire Australian Telehealth Provider
• Neutral Sentiment: Company press release frames the deal as accelerating HIMS’ vision to be a global consumer-health platform; strategic rationale is expansion of personalized-care offerings, but the acquisition adds integration and execution risk. Hims & Hers Announces Agreement to Acquire Eucalyptus
• Neutral Sentiment: Analyst and market commentary is mixed: some note HIMS is oversold with upside potential based on long-term telecom/sexual-wellness trends, while others have trimmed price targets after recent execution and regulatory noise — this creates near-term volatility but also sets up a possible recovery narrative if integration and results meet expectations. Analyst coverage and price-target commentary
• Negative Sentiment: Regulatory and legal overhang persists: Hims & Hers has faced pushback over its GLP‑1/weight-loss play — including scrutiny from regulators and a high-profile lawsuit from Novo Nordisk — which increases litigation risk and could constrain that growth pivot. Hims & Hers GLP-1 pill gambit backfires
• Negative Sentiment: Shareholder litigation risk: a law firm announced an investigation into whether HIMS made misleading disclosures, which could lead to additional legal costs or settlements. This amplifies investor uncertainty even as the company pursues M&A. Schall Law Firm investigation notice

Analyst Ratings Changes

Several brokerages have commented on HIMS. Deutsche Bank Aktiengesellschaft set a $31.00 target price on Hims & Hers Health and gave the stock a “hold” rating in a report on Tuesday, February 10th. Evercore initiated coverage on Hims & Hers Health in a research note on Monday, January 12th. They issued an “in-line” rating and a $33.00 price objective on the stock. Barclays started coverage on shares of Hims & Hers Health in a research report on Monday, December 8th. They set an “overweight” rating and a $48.00 target price for the company. Leerink Partners upgraded shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, December 4th. Finally, UBS Group set a $32.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have issued a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and an average target price of $39.32.

Hims & Hers Health Price Performance

The business has a 50-day moving average of $29.50 and a 200 day moving average of $40.96. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The firm has a market capitalization of $3.61 billion, a P/E ratio of 29.41, a price-to-earnings-growth ratio of 3.04 and a beta of 2.43.

Hims & Hers Health declared that its board has initiated a share repurchase plan on Monday, November 17th that authorizes the company to buyback $250.00 million in shares. This buyback authorization authorizes the company to buy up to 3% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board believes its shares are undervalued.

Insider Activity at Hims & Hers Health

In other news, COO Michael Chi sold 13,750 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $504,762.50. Following the transaction, the chief operating officer owned 305,161 shares in the company, valued at $11,202,460.31. The trade was a 4.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Irene Becklund sold 8,411 shares of the business’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $308,767.81. Following the completion of the transaction, the insider directly owned 2,126 shares in the company, valued at approximately $78,045.46. This represents a 79.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 82,963 shares of company stock valued at $2,944,621 over the last 90 days. Corporate insiders own 13.71% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Hims & Hers Health by 23.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock valued at $12,373,000 after purchasing an additional 78,543 shares during the last quarter. Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health in the first quarter worth about $30,000. Sequoia Financial Advisors LLC bought a new position in shares of Hims & Hers Health in the second quarter valued at approximately $389,000. Envestnet Portfolio Solutions Inc. purchased a new position in Hims & Hers Health during the second quarter valued at approximately $571,000. Finally, Stratos Wealth Partners LTD. bought a new stake in Hims & Hers Health during the 2nd quarter worth approximately $236,000. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.